Silence Therapeutics plc (Silence Therapeutics) is engaged in the research and development of pharmaceutical products. Silence Therapeutics is engaged in the discovery, development and delivery of ribonucleic acid interference (RNAi) therapeutics for the treatment of diseases. The Company�s product, Atu027, is in a phase Ib/2a clinical trial. RNAi platform is built around the AtuRNAi technology and based on stabilization technology, and specific small interfering (siRNA) molecules. A delivery platform using molecules, such as AtuFECT to target a range of organs in the field with: AtuPLEX (for endothelial cells of the vascular system); DBTC (for hepatocytes and hepathic vascular system), and DACC (for vascular endothelial cells of the lung).